. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: J Clin Rheumatol. 2018 Jun;24(4):203–209. doi: 10.1097/RHU.0000000000000736

TABLE 3.

Associations Between Prednisone, Leflunomide, TNFi, Sulfasalazine, and Hydroxychloroquine and BP Outcomes

	Δ SBP	Δ DBP	Odds of a Significant Increase	Odds of Optimal BP
	β (95% CI)	β (95% CI)	OR (95% CI)	OR (95% CI)
Methotrexate	Reference	Reference	Reference	Reference
Prednisone	0.11 (−0.46 to 0.68)	0.48 (0.12 to 0.83)^a	1.18 (1.10 to 1.27)^b	0.97 (0.92 to 1.03)
Leflunomide	1.76 (0.89 to 2.62)^b	1.51 (0.98 to 2.05)^b	1.37 (1.24 to 1.451)^b	0.81 (0.74 to 0.86)^b
TNFi	0.87 (0.20 to 1.54)^c	0.60 (0.18 to 1.03)^a	1.18 (1.08 to 1.28)^b	0.94 (0.87 to 1.01)
Sulfasalazine	1.08 (0.31 to 1.84)^a	0.86 (0.40 to 1.33)^a	1.11 (1.01 to 1.22)^c	0.88 (0.83 to 0.97)^c
Hydroxychloroquine	−0.31 (−0.98 to 0.37)	0.010 (−0.38 to 0.40)	1.01 (0.94 to 1.10)	1.04 (0.98 to 1.11)

Outcomes studied include 6-month change in systolic and diastolic BP, risk of a significant increase in BP, and odds of optimal BP. All therapies are compared with methotrexate after matched weighting for the propensity of receiving the therapy. A significant increase in BP is defined as 20-mm Hg increase in SBP or 10-mm Hg increase in DBP. Optimal BP is defined as <130/90 mm Hg.

P < 0.01.

P < 0.001.

P < 0.05.

OR indicates odds ratio.